Related Experiment Video
Updated: Mar 22, 2026
05:44
Ultrasonographic Evaluation of Breast Cancer-related Lymphedema
Published on: January 12, 2017
10.7K
Identification of Breast Abnormalities Using Feminai-Breast Examination Patch: A Feasibility Study.
Karny Ilan1, Jollanar Mostafa2, Renata Faermann Weidenfeld2
1Feminai LTD, Research and Development, Ramat Gan, Israel; Breast Surgery, Meirav Breast Health Center, Sheba Medical Center, Ramat Gan, Israel.
Clinical Breast Cancer
|March 21, 2026
Summary
The Feminai wearable patch accurately detects abnormal breast findings, showing high sensitivity and negative predictive value for early breast cancer detection. This self-administered tool offers a promising, accessible solution for underserved populations.
Area of Science:
- Oncology
- Biomedical Engineering
- Medical Devices
Background:
- Early breast cancer detection is crucial for reducing mortality.
- Current screening methods face accessibility barriers in low-resource and rural areas.
- The Feminai wearable patch offers a novel approach to self-administered breast examination.
Purpose of the Study:
- To evaluate the accuracy of the Feminai wearable patch in identifying abnormal breast findings.
- To assess the device's potential as an early detection tool for breast cancer.
Main Methods:
- A prospective validation study involving 150 women aged 25-75.
- Participants used the Feminai patch for a 5-minute scan.
- Data from the patch were analyzed using an AI algorithm and compared to mammography, ultrasound, MRI, and biopsy results.
Main Results:
- The Feminai device achieved 96% sensitivity, 82% specificity, and 98% negative predictive value.
- It correctly identified all biopsy-proven malignant lesions.
- The device accurately classified five benign cases as nonsuspicious.
Conclusions:
- The Feminai Breast Examination Kit demonstrates high accuracy, particularly in sensitivity and negative predictive value.
- It shows potential as a remote, cost-effective, and user-friendly early-detection tool.
- Feminai could improve breast cancer screening access in underserved populations.
